Abstract
Nivolumab is the first immuno-oncology drug to demonstrate statistically significant improvement in disease-free survival for the adjuvant treatment of patients with muscle-invasive urothelial carcinoma (MIUC), who are at high risk of recurrence after undergoing radical resection, and who are at high risk of recurrence, compared to placebo (Checkmate 274). The objective of this study was to assess the cost-effectiveness of nivolumab vs surveillance, a proxy of placebo, in MIUC for patients with tumour cell PD-L1≥1% (expressed as tumor proportion score) in Greece.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
